N5-(吡嗪基羰基)-L-鸟氨酸 | 201047-84-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N5-(吡嗪基羰基)-L-鸟氨酸
• 英文名称: Ndelta-Pyrazinylcarbonyl-L-ornithine
• 英文别名: (2S)-2-amino-5-(pyrazine-2-carbonylamino)pentanoic acid
• CAS: 201047-84-9
• 化学式: C₁₀H₁₄N₄O₃
• 分子量: 238.24
• InChiKey: GJGIGJGNECGMMN-ZETCQYMHSA-N

物化性质

• 沸点：
  566.2±50.0 °C(Predicted)
• 密度：
  1.316±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.5
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY
  申请人：Gombert Frank Otto

  公开号：US20130225506A1

  公开（公告）日：2013-08-29

  Novel template-fixed β-hairpin peptidomimetics of the general formula (I), wherein the single elements T or P are α-amino acid residues connected from the carbonyl (C═O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these β-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilisation of stem cells.

  该模板固定的β-折叠肽类似物具有一般式（I），其中单个元素T或P是α-氨基酸残基，从羰基（C═O）连接点连接到顺时针方向下一个元素的氮（N），并且这些元素根据它们在链中的位置在说明书和权利要求中定义，具有作用于CXCR7受体的特性。因此，这些β-折叠肽类似物可用于治疗或预防皮肤疾病、代谢性疾病、炎症性疾病、纤维性疾病、感染性疾病、神经系统疾病、心血管疾病、呼吸系统疾病、胃肠道疾病、泌尿系统疾病、眼科疾病、口腔疾病、血液学疾病和癌症；或干细胞的动员。
• [EN] COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF<br/>[FR] COMPOSÉS COMPRENANT UN LIGAND DE PROTÉINE D'ACTIVATION DES FIBROBLASTES ET LEUR UTILISATION
  申请人：3B PHARMACEUTICALS GMBH

  公开号：WO2022148843A1

  公开（公告）日：2022-07-14

  The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X).

  本发明涉及一种化合物，该化合物包括公式（I）的环肽和附加在Xaa1上的N-末端修饰基团A，其中Xaa1、Xaa2、Xaa3、Xaa4、Xaa5、Xaa6和Xaa7中的任何一个都是氨基酸残基，而Yc是公式（X）的结构。
• TFPI inhibitors and methods of use
  申请人：BAXALTA GMBH

  公开号：US10201586B2

  公开（公告）日：2019-02-12

  The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.

  本发明提供了结合组织因子途径抑制剂（TFPI）的肽，包括TFPI抑制肽及其组合物。这些肽可用于抑制 TFPI、增强凝血因子缺乏症患者的凝血酶形成、增加患者的血凝块形成、治疗患者的血液凝固障碍、纯化 TFPI 以及鉴定 TFPI 结合化合物。
• Conjugate comprising a neurotensin receptor ligand and use thereof
  申请人：3B PHARMACEUTICALS GMBH

  公开号：US10799605B2

  公开（公告）日：2020-10-13

  The present invention is related to a conjugate comprising a structure of general formula (1) [TM1]-[AD1]-[LM]-[AD2]-[TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9 carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK′ is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the following formula (3) wherein ALK′ is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is a bond; or a pharmacologically acceptable salt, solvate or hydrate thereof.

  本发明涉及一种包含通式（1）[TM1]-[AD1]-[LM]-[AD2]-[TM2]（1）结构的共轭物，其中 TM1 是第一靶向分子，其中第一靶向分子能够与第一靶点结合、AD1 是第一适配基团或不存在，LM 是连接基团或不存在，AD2 是第二适配基团或不存在，TM2 是第二靶向基团，其中第二靶向基团能够与第二靶点结合；其中第一靶向分子和/或第二靶向分子是式 (2) 的化合物：其中 R1 选自由氢、甲基和环丙基甲基组成的组； AA-COOH 是选自由 2-氨基-2-金刚烷羧酸、环己基甘氨酸和 9-氨基-双环[3.3.R2选自由(C1-C6)烷基、(C3-C8)环烷基、(C3C8)环烷基甲基、卤素、硝基和三氟甲基组成的组；ALK′为(C2-C5)亚烷基；R3、R4 和 R5 各自独立地选自氢和(C1-C4)烷基组成的组，但 R3、R4 和 R5 中的一个应符合下式(3)，其中 ALK′为(C2-C5)亚烷基；R6 选自氢和(C1-C4)烷基组成的组；R7 为键；或其药理学上可接受的盐、溶液或水合物。
• TFPI INHIBITORS AND METHODS OF USE
  申请人：Baxalta GmbH

  公开号：EP2547355B1

  公开（公告）日：2017-01-11